European urology oncology · 2026
Risk-dependent Benefit of Adjuvant Pembrolizumab in High-risk Clear Cell Renal Cell Carcinoma: A Multi-institutional Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shapiro Daniel D, Roadman Daniel F, Master Viraj A, Peyton Charles C, McIntosh Andrew G, Manley Brandon J, Spiess Philippe E, Lotan Paz, Patil Dattatraya, Dehghanmanshadi Alireza, Amason Reagan, Bouvette Max J, Blittschau Benjamin, Yim Kendrick H, Abreu Nicholas, Jayakumar Vaishnavi, Allen Glenn O, Sexton Wade J, Abel Edwin Jason
Аннотация
BACKGROUND: Adjuvant pembrolizumab improves outcomes in high-risk clear cell renal cell carcinoma (ccRCC), but baseline recurrence risk varies substantially.
OBJECTIVE: To evaluate treatment selection, outcomes, toxicity, and risk-stratified benefit.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort of consecutive patients with KEYNOTE-564-eligible ccRCC treated surgically at five U.S. tertiary centers (2021-2025).
INTERVENTION: Adjuvant pembrolizumab or surveillance, selected through routine care.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Disease-free survival (DFS) was evaluated using a 90-day postoperative landmark, multivariable Cox regression, and inverse probability of treatment weighting (IPTW), stratified by ASSURE risk category. Immune-related adverse events were assessed.
RESULTS AND LIMITATIONS: Among 739 patients, 288 received pembrolizumab and 451 underwent surveillance; median follow-up was 18.4 months. Treated patients had more adverse pathologic features; 16% experienced grade ≥3 immune-related adverse events. The landmark cohort included 686 patients with median follow-up of 19.8 months, including 212 who initiated pembrolizumab by 90 days. Initiation by 90 days was not significantly associated with DFS in unadjusted (hazard ratio 1.02), multivariable-adjusted (0.91), or IPTW analyses (0.90). At 18 months after the landmark, absolute risk differences favoring pembrolizumab were -9.4%, 3.6%, and 5.7% across low-, intermediate-, and high-risk groups, respectively (interaction p = 0.8). Limitations include nonrandomized treatment allocation and limited follow-up.
CONCLUSIONS: Baseline recurrence risk varied markedly among eligible patients. Potential absolute benefit appeared greater with higher baseline risk, although the interaction was nonsignificant. Individualized counseling and improved prognostic and predictive tools remain important.
PATIENT SUMMARY: After kidney cancer surgery, treatment decisions should consider individual recurrence risk and potential side effects. Serious toxicity affected 16% of recipients.
OBJECTIVE: To evaluate treatment selection, outcomes, toxicity, and risk-stratified benefit.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort of consecutive patients with KEYNOTE-564-eligible ccRCC treated surgically at five U.S. tertiary centers (2021-2025).
INTERVENTION: Adjuvant pembrolizumab or surveillance, selected through routine care.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Disease-free survival (DFS) was evaluated using a 90-day postoperative landmark, multivariable Cox regression, and inverse probability of treatment weighting (IPTW), stratified by ASSURE risk category. Immune-related adverse events were assessed.
RESULTS AND LIMITATIONS: Among 739 patients, 288 received pembrolizumab and 451 underwent surveillance; median follow-up was 18.4 months. Treated patients had more adverse pathologic features; 16% experienced grade ≥3 immune-related adverse events. The landmark cohort included 686 patients with median follow-up of 19.8 months, including 212 who initiated pembrolizumab by 90 days. Initiation by 90 days was not significantly associated with DFS in unadjusted (hazard ratio 1.02), multivariable-adjusted (0.91), or IPTW analyses (0.90). At 18 months after the landmark, absolute risk differences favoring pembrolizumab were -9.4%, 3.6%, and 5.7% across low-, intermediate-, and high-risk groups, respectively (interaction p = 0.8). Limitations include nonrandomized treatment allocation and limited follow-up.
CONCLUSIONS: Baseline recurrence risk varied markedly among eligible patients. Potential absolute benefit appeared greater with higher baseline risk, although the interaction was nonsignificant. Individualized counseling and improved prognostic and predictive tools remain important.
PATIENT SUMMARY: After kidney cancer surgery, treatment decisions should consider individual recurrence risk and potential side effects. Serious toxicity affected 16% of recipients.